carla botting malaria vaccines oct 14 2013

PLANNING FOR ADULT VACCINATION WORKSHOP AERAS - SEPT 4, 5, 2013

Carla Botting

Director Product Development and Access

Malaria Vaccines Change from control to elimination/ eradication

2

Malaria epidemiology:

• Globally, 3.3 billion at risk of malaria*

• ~219 million (154M-289M) cases/year, 79% in sub-Saharan Africa

• 90% of these cases are caused by P. falciparum

• ~660,000 (490K-896K) deaths/year, 90% in sub-Saharan Africa

* WHO World Malaria Report 2012

Gething, P.W., et al., A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J, 2011. 10: p. 378.

Pf EIR

>100

10

1

0.1

Malaria Disease Burden

3

2006 Malaria vaccine community goal

Strategic Goal * : To develop an 80% efficacious malaria vaccine by 2025 that would provide protection for at least four years

– Landmark Goal: To develop and license

a first-generation malaria vaccine that has

protective efficacy of more than 50%

against severe disease and death and

lasts longer than one year

Malaria Vaccine Technology Roadmap http://www.malariavaccineroadmap.net/

*WHO is currently leading the process to revise to the Strategic Goal – the Landmark Goal will not change

4 4

Updated Strategic Goal & Outcomes

• A world free of malaria in part due to affordable access to

malaria vaccines that prevent disease and death caused by

and/or interrupt transmission of P. falciparum and P. vivax

in all ages and in all endemic settings.

Goal/Impact

Saving Lives

& Preventing

Disease

Control &

Elimination

Cases

Averted* Outcome Infections

Prevented

Transmission

Interrupted

*Impact on

asymptomatic

reservoir?

5 5

Updated Strategic Goal, Outcomes, & Targets

• A world free of malaria in part due to affordable access to

malaria vaccines that prevent disease and death caused by

and/or interrupt transmission of P. falciparum and P. vivax

in all ages and in all endemic settings.

Sexual/ Sporogonic/ Mosquito

(SSM)

Pre- erythrocytic

(PE)

Blood Stage (BS)

Goal/Impact Saving Lives

& Preventing

Disease

Control &

Elimination

Cases

Averted* Outcome Infections

Prevented

Transmission

Interrupted

Vaccine Target

6 6

Three priority program areas

• A world free of malaria in part due to affordable access to

malaria vaccines that prevent disease and death caused by

and/or interrupt transmission of P. falciparum and P. vivax

in all ages and in all endemic settings.

Goal/Impact

Saving Lives

& Preventing

Disease

Control &

Elimination

Cases

Averted* Outcome Infections

Prevented

Transmission

Interrupted

Vaccine Target

Next Gen TBVs ppRTS,S & eeRTS,S

4 priority program areas

7

RTS,S present and future

ppRTS,S Prevention of pediatric

malaria RTS,S

eeRTS,S Elimination / eradication

RTS,S

eeRTS,S+ Next generation elimination

/ eradication RTS,S

Current TPP for RTS,S, which focuses on prevention of pediatric malaria clinical and severe disease

Evaluation of current RTS,S construct to determine whether it could facilitate elimination in some settings Would require

deploying the current construct to the entire population at risk, not just infants / toddlers

Adding components to the current RTS,S construct to make a more highly efficacious malaria vaccine that could contribute to elimination in an entire at risk population

THANK YOU